Trial Profile
A Phase III, Multicentre, Randomised, Open-label, Parallel, Active-controlled Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Aug 2022
Price :
$35
*
At a glance
- Drugs Triptorelin (Primary)
- Indications Endometriosis
- Focus Therapeutic Use
- Sponsors Ipsen
- 10 Aug 2022 Primary endpoint (Percentage of subjects castrated (E2184 pmol/L or 50 pg/mL)) has been met according to the results published in the Advances in Therapy
- 10 Aug 2022 Results published in the Advances in Therapy
- 19 Dec 2019 Status changed from active, no longer recruiting to completed.